These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 33865336)
1. Correlation between quantitative perfusion histogram parameters of DCE-MRI and PTEN, P-Akt and m-TOR in different pathological types of lung cancer. Zhang B; Zhao Z; Huang Y; Mao H; Zou M; Wang C; Yu G; Zhang M BMC Med Imaging; 2021 Apr; 21(1):73. PubMed ID: 33865336 [TBL] [Abstract][Full Text] [Related]
2. Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer. Zou M; Zhang B; Shi L; Mao H; Huang Y; Zhao Z Sci Rep; 2024 Feb; 14(1):4447. PubMed ID: 38396128 [TBL] [Abstract][Full Text] [Related]
3. [Correlation between DCE-MRI quantitative perfusion histogram parameters, apparent diffusion coefficient and Ki-67 in different pathological types of lung cancer]. Huang YN; Zhao ZH; Mao HJ; Yang JF; Wang T; Zhao L; Yang LM; Yu GM; Wang C Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(21):1645-1650. PubMed ID: 31189264 [No Abstract] [Full Text] [Related]
4. Tumor vascularity and glucose metabolism correlated in adenocarcinoma, but not in squamous cell carcinoma of the lung. Zhang J; Chen L; Chen Y; Wang W; Cheng L; Zhou X; Wang J PLoS One; 2014; 9(3):e91649. PubMed ID: 24614132 [TBL] [Abstract][Full Text] [Related]
5. Comparison of intravoxel incoherent motion diffusion-weighted MR imaging with dynamic contrast-enhanced MRI for differentiating lung cancer from benign solitary pulmonary lesions. Yuan M; Zhang YD; Zhu C; Yu TF; Shi HB; Shi ZF; Li H; Wu JF J Magn Reson Imaging; 2016 Mar; 43(3):669-79. PubMed ID: 26340144 [TBL] [Abstract][Full Text] [Related]
6. Histogram analysis parameters identify multiple associations between DWI and DCE MRI in head and neck squamous cell carcinoma. Meyer HJ; Leifels L; Schob S; Garnov N; Surov A Magn Reson Imaging; 2018 Jan; 45():72-77. PubMed ID: 28963049 [TBL] [Abstract][Full Text] [Related]
7. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071 [TBL] [Abstract][Full Text] [Related]
8. Whole-tumour histogram analysis of pharmacokinetic parameters from dynamic contrast-enhanced MRI in resectable oesophageal squamous cell carcinoma can predict T-stage and regional lymph node metastasis. Chen YL; Li R; Chen TW; Ou J; Zhang XM; Chen F; Wu L; Jiang Y; Laws M; Shah K; Joseph B; Hu J Eur J Radiol; 2019 Mar; 112():112-120. PubMed ID: 30777199 [TBL] [Abstract][Full Text] [Related]
9. Histogram Analysis of ADC Maps for Differentiating Brain Metastases From Different Histological Types of Lung Cancers. Bozdağ M; Er A; Çinkooğlu A Can Assoc Radiol J; 2021 May; 72(2):271-278. PubMed ID: 32602365 [TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced MRI perfusion parameters are imaging biomarkers for angiogenesis in lung cancer. Du Y; Zhang S; Liang T; Shang J; Guo C; Lian J; Gong H; Yang J; Niu G Acta Radiol; 2023 Feb; 64(2):572-580. PubMed ID: 35369721 [TBL] [Abstract][Full Text] [Related]
11. Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma. Kim HS; Kim GY; Lim SJ; Kim YW Pathobiology; 2012; 79(2):84-93. PubMed ID: 22286903 [TBL] [Abstract][Full Text] [Related]
12. NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade. Ma Z; Ma Y; Feng J; Xu Z; Cheng C; Qin J; Li S; Jiang J; Kong R Toxicol Appl Pharmacol; 2024 Apr; 485():116915. PubMed ID: 38537875 [TBL] [Abstract][Full Text] [Related]
13. Application of Dynamic Contrast-Enhanced MRI Parameters for Differentiating Squamous Cell Carcinoma and Malignant Lymphoma of the Oropharynx. Park M; Kim J; Choi YS; Lee SK; Koh YW; Kim SH; Choi EC AJR Am J Roentgenol; 2016 Feb; 206(2):401-7. PubMed ID: 26797371 [TBL] [Abstract][Full Text] [Related]
14. Whole-lesion histogram and texture analyses of breast lesions on inline quantitative DCE mapping with CAIPIRINHA-Dixon-TWIST-VIBE. Sun K; Zhu H; Chai W; Zhan Y; Nickel D; Grimm R; Fu C; Yan F Eur Radiol; 2020 Jan; 30(1):57-65. PubMed ID: 31372782 [TBL] [Abstract][Full Text] [Related]
15. Association Between DCE-MRI Perfusion Histogram Parameters and EGFR and VEGF Expressions in Different Lauren Classifications of Advanced Gastric Cancer. Li Z; Zhao Z; Wang C; Wang D; Mao H; Liu F; Yang Y; Tao F; Lu Z Pathol Oncol Res; 2021; 27():1610001. PubMed ID: 35069035 [No Abstract] [Full Text] [Related]
16. Pulmonary lesions: correlative study of dynamic triple-phase enhanced CT perfusion imaging with tumor angiogenesis and vascular endothelial growth factor expression. Zou M; Zhao Z; Zhang B; Mao H; Huang Y; Wang C BMC Med Imaging; 2021 Oct; 21(1):158. PubMed ID: 34717573 [TBL] [Abstract][Full Text] [Related]
17. Preoperative histogram parameters of dynamic contrast-enhanced MRI as a potential imaging biomarker for assessing the expression of Ki-67 in prostate cancer. Zhang Y; Li Z; Gao C; Shen J; Chen M; Liu Y; Cao Z; Pang P; Cui F; Xu M Cancer Med; 2021 Jul; 10(13):4240-4249. PubMed ID: 34117733 [TBL] [Abstract][Full Text] [Related]
18. Histogram analysis of dynamic contrast-enhanced magnetic resonance imaging to predict extramural venous invasion in rectal cancer. Wang KX; Yu J; Xu Q BMC Med Imaging; 2023 Jun; 23(1):77. PubMed ID: 37291527 [TBL] [Abstract][Full Text] [Related]
19. Use of diffusion kurtosis imaging and quantitative dynamic contrast-enhanced MRI for the differentiation of breast tumors. Li T; Yu T; Li L; Lu L; Zhuo Y; Lian J; Xiong Y; Kong D; Li K J Magn Reson Imaging; 2018 Nov; 48(5):1358-1366. PubMed ID: 29717790 [TBL] [Abstract][Full Text] [Related]
20. Dynamic contrast-enhanced MRI predicts PTEN protein expression which can function as a prognostic measure of progression-free survival in NPC patients. Wu G; Huang W; Xu J; Li W; Wu Y; Yang Q; Liu K; Zhu M; Balasubramanian PS; Li M J Cancer Res Clin Oncol; 2022 Jul; 148(7):1771-1780. PubMed ID: 34398299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]